GenMark raises $75 million in bumped-up follow-on

Molecular diagnostics company GenMark Diagnostics Inc. (NASDAQ:GNMK) raised $75 million through the sale of 7.6 million shares at $9.84 in a bumped-up follow-on underwritten by JPMorgan; William Blair; Canaccord; and Cowen. GenMark said it planned to raise $60 million in the offering late Monday, when its price was $9.72. The company has 510(k) clearance from FDA for its cystic fibrosis (CF) genotyping, warfarin sensitivity, thrombophilia risk and respiratory viral panel tests for use on its XT-8 System, an automated molecular diagnostic platform. ...